Lemke Matthias R, Brecht H Michael, Koester Juergen, Kraus Peter H, Reichmann Heinz
Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany.
J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):214-20. doi: 10.1176/jnp.17.2.214.
Anhedonia, a core symptom of depression, correlates with motor alterations in major depressive disorder and has been assumed to be frequent in depressed patients with Parkinson's disease (PD). In the present study, the authors assessed for the first time frequency of anhedonia in patients with idiopathic Parkinson's disease (N = 657) and the relationship of anhedonia and parkinsonian motor deficits during treatment with pramipexole. Mild depression was present in 47% of the patients and moderate to severe depression in 22%. Anhedonic individuals included 45.7% of all patients and 79.7% of depressed Parkinson's disease patients. Anhedonic Parkinson's disease patients had greater motor deficits, restrictions in activities of daily living, and depression compared to nonanhedonic patients. Frequency of anhedonia and depression was significantly reduced during treatment with pramipexole. Future studies should further investigate antianhedonic efficacy of dopamine agonists including pramipexole in depressed patients with Parkinson's disease.
快感缺失是抑郁症的核心症状，与重度抑郁症中的运动改变相关，并且被认为在帕金森病（PD）抑郁症患者中很常见。在本研究中，作者首次评估了特发性帕金森病患者（N = 657）中快感缺失的发生率，以及在使用普拉克索治疗期间快感缺失与帕金森运动功能障碍的关系。47%的患者存在轻度抑郁，22%的患者存在中度至重度抑郁。快感缺失个体占所有患者的45.7%，占抑郁症帕金森病患者的79.7%。与无快感缺失的患者相比，有快感缺失的帕金森病患者有更严重的运动功能障碍、日常生活活动受限和抑郁症状。在使用普拉克索治疗期间，快感缺失和抑郁的发生率显著降低。未来的研究应进一步调查多巴胺激动剂（包括普拉克索）对帕金森病抑郁症患者的抗快感缺失疗效。
Zotero 插件